{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:48:46Z","timestamp":1785808126427,"version":"3.56.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To investigate the association between primary tumor metabolic parameters on\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT and lymph node metastasis (LNM) in treatment-na\u00efve anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), and to evaluate their utility in discriminating the cases with radiographically occult LNM (OLNM).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 157 patients with pathologically confirmed ALK-positive NSCLC who underwent\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT before the treatment between October 2021 and December 2024. Primary tumor metabolic parameters, including SUVmax, SUVpeak, metabolic tumor volume (MTV), and total lesion glycolysis (TLG), were measured. Logistic regression analyses were performed to identify LNM predictors. Receiver operating characteristic curve analysis evaluated predictive performance, with area under the curve (AUC) was calculated. The relation between OLNM status and metabolic parameters of primary tumor was analyzed using Kruskal-Wallis test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 157 patients (62 males and 95 females; mean age 56\u2009\u00b1\u200911 years), 71 patients (45.2%) had pathologically confirmed LNM. Patients with LNM exhibited evidently larger primary tumor size and higher SUVmax, SUVpeak, MTV, and TLG than those without LNM (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Univariate analysis showed primary tumor size, SUVmax, SUVpeak, MTV, and TLG were remarkedly associated with LNM. Multivariate analysis identified primary tumor size (OR: 1.043, 95%CI: 1.004\u20131.084;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.032) and SUVmax (OR: 1.322, 95%CI: 1.159\u20131.532;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) as independent predictors. The AUCs for tumor size, SUVmax, and combined factors were 0.76, 0.77, and 0.81, respectively. In addition, false-negative (OLNM-positive) cases showed markedly larger tumor size (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.003) and higher TLG (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.011) than true-negative cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Metabolic parameters of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT before treatment, particularly when combined with primary tumor size, may help stratify LNM risk in treatment-na\u00efve ALK-positive NSCLC patients. These parameters may help identify OLNM, potentially guiding personalized lymph node dissection strategies and optimizing treatment plans.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40644-026-01058-0","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:06:47Z","timestamp":1780049207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive value of primary tumor 18F-FDG PET\/CT metabolic parameters for lymph node metastasis in treatment-na\u00efve ALK-positive NSCLC"],"prefix":"10.1186","volume":"26","author":[{"given":"Tingting","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangchun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"7153","key":"1058_CR1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561\u20136.","journal-title":"Nature"},{"issue":"1","key":"1058_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/JTO.0b013e31815e8b60","volume":"3","author":"K Inamura","year":"2008","unstructured":"Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3(1):13\u20137.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"1058_CR3","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","volume":"36","author":"JJ Lin","year":"2018","unstructured":"Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, et al. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. J Clin Oncol. 2018;36(12):1199\u2013206.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1058_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/cac2.12658","volume":"45","author":"S Baek","year":"2025","unstructured":"Baek S, Sung E, Kim G, Hong MH, Lee CY, Shim HS, et al. Single-cell multi-omics reveals tumor microenvironment factors underlying poor immunotherapy responses in ALK-positive lung cancer. Cancer Commun (Lond). 2025;45(4):422\u20137.","journal-title":"Cancer Commun (Lond)"},{"key":"1058_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2017.11.001","volume":"114","author":"HX Tian","year":"2017","unstructured":"Tian HX, Zhang XC, Yang JJ, Guo WB, Chen ZH, Wang Z, et al. Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients. Lung Cancer. 2017;114:90\u20135.","journal-title":"Lung Cancer"},{"key":"1058_CR6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.2147\/CMAR.S147569","volume":"10","author":"K Seto","year":"2018","unstructured":"Seto K, Kuroda H, Yoshida T, Sakata S, Mizuno T, Sakakura N, et al. Higher frequency of occult lymph node metastasis in clinical N0 pulmonary adenocarcinoma with ALK rearrangement. Cancer Manag Res. 2018;10:2117\u201324.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"1058_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/tlcr-23-606","volume":"13","author":"A Zeng","year":"2024","unstructured":"Zeng A, Xiong Y, Zhang J, Yu H, Zhang L, Bian D, et al. Prognostic factors of resectable anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) patients: a retrospective analysis based on a single center. Transl Lung Cancer Res. 2024;13(1):16\u201333.","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"1058_CR8","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jtho.2024.07.009","volume":"19","author":"K Parikh","year":"2024","unstructured":"Parikh K, Dimou A, Leventakos K, Mansfield AS, Shanshal M, Wan Y, et al. Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database. J Thorac Oncol. 2024;19(11):1539\u201349.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"1058_CR9","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/cac2.12593","volume":"44","author":"L Li","year":"2024","unstructured":"Li L, Li W, Wu C, Xi Y, Guo L, Ji Y, et al. Real-world data on ALK rearrangement test in Chinese advanced non-small cell lung cancer (RATICAL): a nationwide multicenter retrospective study. Cancer Commun (Lond). 2024;44(9):992\u20131004.","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"1058_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-018-0810-4","volume":"17","author":"B Golding","year":"2018","unstructured":"Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. 2018;17(1):52.","journal-title":"Mol Cancer"},{"issue":"11","key":"1058_CR11","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S1470-2045(11)70232-7","volume":"12","author":"AT Shaw","year":"2011","unstructured":"Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12(11):1004\u201312.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1058_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00408-020-00378-7","volume":"198","author":"X Zhou","year":"2020","unstructured":"Zhou X, Wu C, Cheng Q. Negative Lymph Node Count Predicts Survival of Resected Non-small Cell Lung Cancer. Lung. 2020;198(5):839\u201346.","journal-title":"Lung"},{"issue":"1","key":"1058_CR13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1186\/s12885-023-11189-3","volume":"23","author":"JS Cai","year":"2023","unstructured":"Cai JS, Yang F, Wang X. Occult lymph node metastasis is not a favorable factor for resected NSCLC patients. BMC Cancer. 2023;23(1):822.","journal-title":"BMC Cancer"},{"issue":"32","key":"1058_CR14","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1200\/JCO.2011.35.2500","volume":"29","author":"VW Rusch","year":"2011","unstructured":"Rusch VW, Hawes D, Decker PA, Martin SE, Abati A, Landreneau RJ, et al. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol. 2011;29(32):4313\u20139.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1058_CR15","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1097\/RLU.0b013e318217adc9","volume":"36","author":"S Tanabe","year":"2011","unstructured":"Tanabe S, Naomoto Y, Shirakawa Y, Fujiwara Y, Sakurama K, Noma K, et al. F-18 FDG PET\/CT contributes to more accurate detection of lymph nodal metastasis from actively proliferating esophageal squamous cell carcinoma. Clin Nucl Med. 2011;36(10):854\u20139.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"1058_CR16","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/cncr.10330","volume":"94","author":"H Kato","year":"2002","unstructured":"Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer. 2002;94(4):921\u20138.","journal-title":"Cancer"},{"issue":"1","key":"1058_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00432-019-03054-3","volume":"146","author":"MR Bae","year":"2020","unstructured":"Bae MR, Roh JL, Kim JS, Lee JH, Cho KJ, Choi SH, et al. (18)F-FDG PET\/CT versus CT\/MR imaging for detection of neck lymph node metastasis in palpably node-negative oral cavity cancer. J Cancer Res Clin Oncol. 2020;146(1):237\u201344.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1058_CR18","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1038\/s41467-024-47512-0","volume":"15","author":"SJ Sujit","year":"2024","unstructured":"Sujit SJ, Aminu M, Karpinets TV, Chen P, Saad MB, Salehjahromi M, et al. Enhancing NSCLC recurrence prediction with PET\/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun. 2024;15(1):3152.","journal-title":"Nat Commun"},{"issue":"7","key":"1058_CR19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/RLU.0000000000005910","volume":"50","author":"X Tao","year":"2025","unstructured":"Tao X, Zhang Q, Li N, Wang S, Guo W, Yuan P, et al. Prognostic Value of 18F-FDG PET\/CT in Neoadjuvant PD-1 Inhibitor-treated NSCLC: A Five-year Follow-up Study. Clin Nucl Med. 2025;50(7):577\u201387.","journal-title":"Clin Nucl Med"},{"key":"1058_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.lungcan.2021.06.024","volume":"159","author":"RD Seban","year":"2021","unstructured":"Seban RD, Assie JB, Giroux-Leprieur E, Massiani MA, Bonardel G, Chouaid C, et al. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET\/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. Lung Cancer. 2021;159:45\u201355.","journal-title":"Lung Cancer"},{"key":"1058_CR21","doi-asserted-by":"publisher","first-page":"974934","DOI":"10.3389\/fonc.2022.974934","volume":"12","author":"J Qiao","year":"2022","unstructured":"Qiao J, Zhang X, Du M, Wang P, Xin J. (18)F-FDG PET\/CT radiomics nomogram for predicting occult lymph node metastasis of non-small cell lung cancer. Front Oncol. 2022;12:974934.","journal-title":"Front Oncol"},{"issue":"9","key":"1058_CR22","doi-asserted-by":"publisher","first-page":"3190","DOI":"10.1007\/s00259-025-07177-3","volume":"52","author":"C Mingels","year":"2025","unstructured":"Mingels C, Madani MH, Sen F, Nalbant H, Riess JW, Abdelhafez YG, et al. Diagnostic accuracy in NSCLC lymph node staging with Total-Body and conventional PET\/CT. Eur J Nucl Med Mol Imaging. 2025;52(9):3190\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1058_CR23","doi-asserted-by":"publisher","first-page":"1278464","DOI":"10.3389\/fonc.2024.1278464","volume":"14","author":"CZ Jiang","year":"2024","unstructured":"Jiang CZ, Zheng K, Zhang YY, Yang J, Ye H, Peng X. (18)F-FDG PET\/CT semi-quantitative parameters combined with SCC-Ag in predicting lymph node metastasis in stage I-II cervical cancer. Front Oncol. 2024;14:1278464.","journal-title":"Front Oncol"},{"issue":"5","key":"1058_CR24","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00330-019-06622-w","volume":"30","author":"KE Fasmer","year":"2020","unstructured":"Fasmer KE, Gulati A, Dybvik JA, Ytre-Hauge S, Salvesen O, Trovik J, et al. Preoperative 18F-FDG PET\/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer. Eur Radiol. 2020;30(5):2443\u201353.","journal-title":"Eur Radiol"},{"issue":"2","key":"1058_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000509988","volume":"99","author":"HY Seol","year":"2021","unstructured":"Seol HY, Kim YS, Kim SJ. Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography\/Computed Tomography for Assessment of Occult Lymph Node Metastasis in Non-Small Cell Lung Cancer. Oncology. 2021;99(2):96\u2013104.","journal-title":"Oncology"},{"issue":"1","key":"1058_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00432-022-04545-6","volume":"149","author":"M Wang","year":"2023","unstructured":"Wang M, Liu L, Dai Q, Jin M, Huang G. Developing a primary tumor and lymph node 18F-FDG PET\/CT-clinical (TLPC) model to predict lymph node metastasis of resectable T2-4 NSCLC. J Cancer Res Clin Oncol. 2023;149(1):247\u201361.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"1058_CR27","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.3390\/curroncol31090379","volume":"31","author":"V Fuorivia","year":"2024","unstructured":"Fuorivia V, Attili I, Corvaja C, Asnaghi R, Carnevale Schianca A, Trillo Aliaga P, et al. Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario. Curr Oncol. 2024;31(9):5121\u201339.","journal-title":"Curr Oncol"},{"issue":"3","key":"1058_CR28","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jtcvs.2010.11.008","volume":"141","author":"GE Darling","year":"2011","unstructured":"Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg. 2011;141(3):662\u201370.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"1058_CR29","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.athoracsur.2020.05.166","volume":"111","author":"GD Jones","year":"2021","unstructured":"Jones GD, Caso R, Choe G, Tan KS, Connolly JG, Dycoco J, et al. Intentional Segmentectomy for Clinical T1 N0 Non-small Cell Lung Cancer: Survival Differs by Segment. Ann Thorac Surg. 2021;111(3):1028\u201335.","journal-title":"Ann Thorac Surg"},{"key":"1058_CR30","doi-asserted-by":"publisher","first-page":"1422623","DOI":"10.3389\/fonc.2024.1422623","volume":"14","author":"L Zhang","year":"2024","unstructured":"Zhang L, Zhang F, Li G, Xiang X, Liang H, Zhang Y. Predicting lymph node metastasis of clinical T1 non-small cell lung cancer: a brief review of possible methodologies and controversies. Front Oncol. 2024;14:1422623.","journal-title":"Front Oncol"},{"issue":"14","key":"1058_CR31","doi-asserted-by":"publisher","first-page":"13271","DOI":"10.1007\/s00432-023-05190-3","volume":"149","author":"G Guner","year":"2023","unstructured":"Guner G, Aktas BY, Basal FB, Demirkazik A, Gursoy P, Demirci U, et al. Is there any prognostic significance in pleural involvement and\/or effusion in patients with ALK-positive NSCLC? J Cancer Res Clin Oncol. 2023;149(14):13271\u20137.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"20","key":"1058_CR32","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1158\/1078-0432.CCR-10-0099","volume":"16","author":"Y Sakairi","year":"2010","unstructured":"Sakairi Y, Nakajima T, Yasufuku K, Ikebe D, Kageyama H, Soda M, et al. EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Clin Cancer Res. 2010;16(20):4938\u201345.","journal-title":"Clin Cancer Res"},{"key":"1058_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lungcan.2019.08.010","volume":"136","author":"R Descourt","year":"2019","unstructured":"Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, et al. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). Lung Cancer. 2019;136:109\u201314.","journal-title":"Lung Cancer"},{"issue":"1","key":"1058_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12880-023-01004-7","volume":"23","author":"X Liao","year":"2023","unstructured":"Liao X, Liu M, Li S, Huang W, Guo C, Liu J, et al. The value on SUV-derived parameters assessed on (18)F-FDG PET\/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer. BMC Med Imaging. 2023;23(1):49.","journal-title":"BMC Med Imaging"},{"issue":"11","key":"1058_CR35","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.21037\/tlcr-24-450","volume":"13","author":"C Xu","year":"2024","unstructured":"Xu C, Sun J, Liu H, Chen B, Wu S, Qiu H, et al. Analysis of the lymph node metastasis distribution in patients with invasive resectable non-small cell lung cancer. Transl Lung Cancer Res. 2024;13(11):3039\u201349.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"1058_CR36","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12890-024-03345-7","volume":"24","author":"B Wu","year":"2024","unstructured":"Wu B, Zhu Y, Hu Z, Wu J, Zhou W, Si M, et al. Machine learning predictive models and risk factors for lymph node metastasis in non-small cell lung cancer. BMC Pulm Med. 2024;24(1):526.","journal-title":"BMC Pulm Med"},{"key":"1058_CR37","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.3389\/fonc.2020.01322","volume":"10","author":"Y Wu","year":"2020","unstructured":"Wu Y, Han C, Wang Z, Gong L, Liu J, Chong Y, et al. An Externally-Validated Dynamic Nomogram Based on Clinicopathological Characteristics for Evaluating the Risk of Lymph Node Metastasis in Small-Size Non-small Cell Lung Cancer. Front Oncol. 2020;10:1322.","journal-title":"Front Oncol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01058-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01058-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01058-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:21:46Z","timestamp":1785806506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01058-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01058-0","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study adhered strictly to the principles of the helsinki declaration and received approval from the ethics committee of all participating institutions. Given the retrospective nature of this study, the requirement for individual consent was waived.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"96"}}